LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Lab-on-Paper Developed for Rapid Inexpensive Medical Diagnostics

By LabMedica International staff writers
Posted on 15 Mar 2015
Image: Schematics of the unique fluid transport property of the platform is demonstrated in the figure using dye-containing fluids (Photo courtesy of Labonachip LLC).
Image: Schematics of the unique fluid transport property of the platform is demonstrated in the figure using dye-containing fluids (Photo courtesy of Labonachip LLC).
A new paper-based platform has been created for conducting a wide range of complex medical diagnostics including Lyme disease, human immunodeficiency virus, Ebolavirus disease and malaria.

The key development was the invention of fluid actuated valves embedded in the paper that allow for sequential manipulation of sample fluids and multiple reagents in a controlled manner to perform complex multistep immune-detection tests without human intervention.

A team of engineers at the University of Rhode Island (URI; Kingston, RI, USA) used the principle of paper-based lateral flow test strips where sample fluid wicks along a strip of paper, reacts with embedded reagents, and produces a colored signal result. However, more complex medical diagnostics such as enzymatic assay protocols require multiple reagents triggered at particular times during the process, which can only be accomplished autonomously using the proprietary microfluidic valve technology created by the engineers.

The lab-on-paper devices are constructed with multiple layers of paper printed with wax to create a three-dimensional structure of valves and channels along which the fluid travels, triggering the reagents at the appropriate time and generating a result. This new paper-based technology is the next generation of the lab-on-a-chip device the team reported in 2011, which has been further refined since then. That device is now smaller and employs an innovative micropump for precise fluid movement within the cartridge's microchannels.

The scientists have already succeeded in performing a feasibility study of their technology by detecting a biomarker for sepsis, a life-threatening complication from an infection. ProThera Biologics (East Providence, RI, USA) identified a biomarker that indicates a patient is going into shock from sepsis, and the company has collaborated with the URI engineers to develop a paper-based rapid test using this biomarker, and have established a startup company, Labonachip LLC (North Kingstown, RI, USA) to commercialize their technologies.

Mohammad Faghri, PhD, a professor of Mechanical Engineering and Applied Mechanics, and inventor of the platform said, “We combined the well-established test strip technology, micro-patterning techniques and our innovative paper-based valves to create a new class of strip tests that are capable of autonomously handling multiple reagents. The sample fluid activates the flow of reagents in a predetermined sequence and time. When combined with an optical reader, which could even be a conventional smart phone, the lab-on-paper device provides accurate quantitative results.”

Related Links:

University of Rhode Island
ProThera Biologics
Labonachip LLC


Gold Member
Fibrinolysis Assay
HemosIL Fibrinolysis Assay Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
HBV DNA Test
GENERIC HBV VIRAL LOAD VER 2.0
Hemodynamic System Monitor
OptoMonitor

Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more